<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The development of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> has been linked to lowered levels of epoxyeicosatrienoic acids (EETs) in the cardiovascular system </plain></SENT>
<SENT sid="1" pm="."><plain>Ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is caused by <z:mp ids='MP_0005338'>atherosclerotic lesions</z:mp> in multi-coronary arteries especially diffusive lesions, which can lead to severe myocardial dysfunction, heart enlargement, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, or <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, and so on </plain></SENT>
<SENT sid="2" pm="."><plain>The EETs are metabolized by the soluble <z:chebi fb="0" ids="32955">epoxide</z:chebi> hydrolase (sEH) encoded by the EPHX2 gene that has several known polymorphisms </plain></SENT>
<SENT sid="3" pm="."><plain>CONTENT: The EPHX2 gene polymorphism is associated with sEH catalytic activity and various <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>sEH is distributed in a variety of organs and tissues and regulated by multiple factors </plain></SENT>
<SENT sid="5" pm="."><plain>Research in the area has led to the presence of multiple powerful soluble <z:chebi fb="0" ids="32955">epoxide</z:chebi> hydrolase inhibitors (sEHIs), whose molecular structure and function has been optimized gradually </plain></SENT>
<SENT sid="6" pm="."><plain>sEHIs increase EETs' concentration by inhibiting hydration of EETs into their corresponding vicinal <z:chebi fb="0" ids="23824">diols</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>EETs are important signaling molecules and known as endothelium-derived hyperpolarizing factors (EDHF) </plain></SENT>
<SENT sid="8" pm="."><plain>sEHIs have been developed for their ability to prevent <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, dilate the coronary artery, promote <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, ameliorate postischemic recovery of heart contractile function, decrease <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury, modulate postischemic <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, and prevent <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>SUMMARY: sEH is one of the etiological factors of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e>, and plays an important role in the progression of myocardium <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This indicates that sEHIs provide a new method for the prevention and treatment of ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>